IN
INSM.US Insmed Inc
- Market cap
- USD 26.6B
- P/E
- -
- P/B
- 36.60x
- ROE
- -50.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INSM.US undervalued?
Graham numberThe Graham number of Insmed Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Insmed Inc fundamental analysis
No fundamental analysis for Insmed Inc yet.
Insmed Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral r…
Full company profileInsmed Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Insmed Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 9.84M | 136M | 164M | 188M | 245M | 305M | 364M | 606M | 1.67B |
| Gross Profit | -2.44M | -2.90M | 7.41M | 112M | 125M | 144M | 190M | 240M | 278M | 482M | 1.41B |
| Operating Income | -173M | -189M | -307M | -235M | -265M | -375M | -457M | -710M | -878M | -1.18B | -388M |
| EBITDA | -170M | -184M | -295M | -217M | -250M | -384M | -447M | -660M | -819M | -1.17B | -256M |
| Net Income | -176M | -193M | -324M | -254M | -294M | -435M | -482M | -750M | -914M | -1.28B | -369M |
| EPS | -2.85 | -2.89 | -4.22 | -3.01 | -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -5.98 | -1.69 |
| Balance Sheet | |||||||||||
| Total Assets | 238M | 462M | 605M | 742M | 796M | 1.24B | 1.66B | 1.33B | 2.03B | 2.26B | 2.23B |
| Total Liabilities | 83.5M | 101M | 396M | 481M | 520M | 833M | 1.57B | 1.66B | 1.74B | 1.53B | 1.50B |
| Shareholders' Equity | 154M | 361M | 208M | 262M | 276M | 410M | 88.0M | -332M | 285M | 739M | 726M |
| Cash & Short-term Investments | 163M | 381M | 495M | 487M | 533M | 717M | 1.15B | 780M | 1.43B | 1.43B | 1.15B |
| Total Debt | 54.8M | 55.6M | 317M | 397M | 405M | 612M | 1.18B | 1.20B | 1.31B | 768M | 741M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -147M | -160M | -258M | -251M | -219M | -363M | -400M | -536M | -684M | -935M | -464M |
| Capital Expenditure | 4.20M | 3.00M | 14.8M | 42.3M | 6.82M | 7.29M | 9.88M | 13.3M | 21.9M | 32.6M | 20.5M |
| Free Cash Flow | -151M | -163M | -273M | -293M | -226M | -371M | -410M | -550M | -706M | -968M | -485M |
| Ratios | |||||||||||
| ROE | -114.1% | -53.4% | -155.7% | -97.2% | -106.6% | -105.9% | -547.5% | - | -320.2% | -172.8% | -50.9% |
| ROA | -74.1% | -41.7% | -53.6% | -34.3% | -36.9% | -35.0% | -29.1% | -56.4% | -45.1% | -56.4% | -16.6% |
| Net Profit Margin | - | - | -3,297.2% | -186.4% | -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% | -22.1% |
| Debt to Equity | 0.35x | 0.15x | 1.52x | 1.52x | 1.47x | 1.49x | 13.39x | - | 4.60x | 1.04x | 1.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Insmed Inc dividends
Insmed Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Mar 3, 2011.
Who owns Insmed Inc
- Insiders 1.01%
- Institutions 98.99%
- Public & others 0.00%
- Shares outstanding 219M
- Free float 218M
Top funds holding INSM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 6.95M | 3.17% | +0.84% | Sep 2026 |
| American Funds Growth Fd of Amer A | 6.75M | 3.08% | +7.93% | Sep 2026 |
| Vanguard Small Cap Index | 2.46M | 1.12% | -1.44% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 2.34M | 1.07% | -0.26% | Sep 2026 |
| Vanguard MStar Growth Index Investor | 1.93M | 0.88% | +7.98% | Sep 2026 |
| iShares Biotechnology ETF | 1.67M | 0.76% | -0.32% | Oct 2026 |
| Fidelity Advisor Growth Opps M | 1.65M | 0.75% | 0.00% | Sep 2026 |
| JPMorgan Mid Cap Growth I | 1.52M | 0.69% | -1.56% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.50M | 0.68% | +26.46% | Sep 2026 |
| JPMorgan Growth Advantage A | 1.46M | 0.67% | -2.20% | Sep 2026 |
| Polar Capital Biotech S Inc | 1.45M | 0.66% | 0.00% | Sep 2026 |
| Orbis Global Equity Investor | 1.44M | 0.66% | +249.59% | Jun 2026 |
| JPMorgan Large Cap Growth I | 1.43M | 0.65% | -0.91% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.37M | 0.62% | -4.49% | Sep 2026 |
| Fidelity Select Biotechnology | 1.24M | 0.57% | +0.07% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.23M | 0.56% | +2.68% | Oct 2026 |
| iShares Russell Mid-Cap Growth ETF | 1.21M | 0.55% | -0.07% | Oct 2026 |
| American Funds IS® Growth 1 | 1.06M | 0.48% | +2.46% | Sep 2026 |
| Fidelity Extended Market Index | 1.00M | 0.46% | -5.28% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 911K | 0.42% | -0.06% | Oct 2026 |
Top institutions holding INSM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 16.1M | 7.36% | +22.67% | Jun 2026 |
| BlackRock Inc | 15.8M | 7.21% | -5.22% | Jun 2026 |
| JPMorgan Chase & Co | 10.4M | 4.75% | -56.82% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 10.4M | 4.74% | +0.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 9.79M | 4.46% | +1.54% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 9.35M | 4.26% | +13.53% | Sep 2026 |
| Baker Bros Advisors LP | 8.80M | 4.01% | +18.53% | Jun 2026 |
| Darwin Global Management, Ltd. | 6.43M | 2.93% | -61.73% | Jun 2026 |
| Ameriprise Financial Inc | 6.18M | 2.82% | +102.10% | Jun 2026 |
| Orbis Allan Gray Ltd | 6.08M | 2.77% | +224.46% | Jun 2026 |
| State Street Corp | 6.05M | 2.76% | +9.01% | Jun 2026 |
| D. E. Shaw & Co LP | 5.88M | 2.68% | +4.48% | Jun 2026 |
| Artisan Partners Limited Partnership | 5.44M | 2.48% | -16.63% | Jun 2026 |
| RTW INVESTMENTS, LLC | 4.84M | 2.21% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 4.22M | 1.92% | -5.17% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.41M | 1.55% | +10.10% | Jun 2026 |
| NORGES BANK | 3.38M | 1.54% | +16.03% | Jun 2026 |
| Jupiter Topco LLC | 2.61M | 1.19% | 0.00% | Jun 2026 |
| UBS Group AG | 2.58M | 1.18% | +48.75% | Jun 2026 |
| Citadel Advisors Llc | 2.56M | 1.17% | +17.15% | Jun 2026 |
Insmed Inc company profile
- Company name
- Insmed Inc
- Ticker
- INSM.US
- Exchange
- USA Stocks
- Listed since
- Jun 1, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,664
- Fiscal year end
- December
- Address
- 700 US Highway 202/206, Bridgewater, NJ, United States, 08807
- Phone
- 908 977 9900
- Website
- insmed.com
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Inc management
10- Mr. William H. Lewis J.D., M.B.A.President, CEO & Chairman · born 1969
- Mr. Roger Adsett M.B.A.Chief Operating Officer · born 1969
- Mr. Michael Alexander Smith J.D.Chief Legal Officer & Corporate Secretary · born 1978
- Dr. Martina Flammer M.B.A., M.D.Chief Medical Officer · born 1964
- Mr. Brendan O'Leary C.F.A.Senior Vice President of Finance
- Mr. Brian K. Kaspar Ph.D.Chief Scientific Officer · born 1974
- Bryan DunnVice President of Investor Relations
- Ms. Christie CamelioChief Compliance Officer
- Ms. Claire MulhearnVice President of Corporate Communications
- Ms. S. Nicole Schaeffer M.B.A.Chief People Strategy Officer · born 1968